Skip to content
X
![]()
X
Zenkuda and Tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD
Zenkuda Demonstrates a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval in wAMD
×
FORWARD LOOKING STATEMENTS
This site contains forward-looking statements and information. The use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Actual results could differ materially from those projected in such forward-looking statements.